Shots:
- Novanta has entered into a definitive agreement to acquire Riverpoint Medical from Arlington Capital Partners, expanding Novanta’s presence in the minimally invasive surgery market
- As per the deal, Novanta will acquire Riverpoint for $1.2B upfront, with $250M in milestone payments expected in Q1’27, representing the total deal value of $1.45B; closing is anticipated in Q3’26
- Acquisition will add Riverpoint’s portfolio of surgical fibers, minimally invasive surgical consumables & instruments, implants, complex assemblies, & proprietary coating technologies that are used across sports medicine, trauma, & CV surgery
Ref: Businesswire | Image: Riverpoint Medical | Press Release
Related News: Johnson & Johnson to Acquire Firefly Bio for $1B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
